In the treatment of various cancers, anti-VEGF therapy has been included in the standard therapeutic protocol for hypervascular cancers such as renal cell carcinoma (RCC), colorectal cancer with liver metastases, ovarian cancer with ascites, and non-small cell lung cancer. This evidence concerns the gene VEGFA and renal cell carcinoma.